AMGN Stock Price Today (July 2026) — Amgen Inc. Analysis & Key Metrics 2026-07-17
Amgen Inc. (AMGN) is trading at $366.29, down 1.42% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $352.77 (-3.7% upside).
- Volatility remains elevated (22.24% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.80% YoY) alongside significant competitive pressures.
AMGN Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Amgen Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $240.72B
P/E Ratio
Forward P/E: 15.43
Revenue Growth
Year over Year
Analyst Target
+-3.7% upside potential
Key Investor Questions About AMGN
What investors need to know before buying
Based on current market data, AMGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 56.33)
- Fundamentals say: Caution warranted (high leverage concerns)
AMGN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AMGN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $57.32B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AMGN stock traded between $269.77 and $391.29—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 22.24% annualized volatility and β=0.47, the stock exhibits low sensitivity to market moves—making AMGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.
The $5.25 billion ETF paying dividends that grew three years straight right now
DIVO has raised its monthly payout three years running and sits on $5.25 billion in assets, but one holding carries a debt load that raises questions about how long the streak can continue.
Seagate Stock And The Bet On A Denser Future
Management is promising structural growth without shipping more drives, and the market is buying it. But the real test of that high-tech promise is around the corner.
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
Zenas BioPharma (ZBIO) remains undervalued, as investor concerns over its phase 3 INDIGO trial for o
Fortinet Stock Is Pricing In A Much Bigger Future
Management laid out a bigger vision for the business, and investors have more than agreed. The question now is how much of that future is already in the price.
Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
It’s the first pill that lowers blood cholesterol far better than statins, medicines that a quarter of adults take to reduce their risk of heart attack and stroke.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion
Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.
What Could Push LLY Stock Higher From Here?
While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.
Frequently Asked Questions
Common investor questions about Amgen Inc.
Amgen Inc. (AMGN) is currently trading at $366.29. The RSI (14-day) is at 56.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $352.77 implies 3.7% downside from current levels. Volatility is moderate at 22.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amgen Inc. (AMGN): The trailing P/E ratio is 25.47, which is in line with broader market averages. The forward P/E is 15.43, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.98, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 21.51. Price-to-Sales is 5.31. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 30 analysts covering AMGN, the consensus price target is $352.77. This represents a 3.7% downside from the current price of $366.29. The range spans from a low target of $200.00 to a high target of $427.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Amgen Inc. (AMGN) pays a dividend with a current yield of approximately 2.75%. The annualized dividend rate is $9.66 per share. The payout ratio is 67.2%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-05-15T00:00:00.000Z.
Key risks for Amgen Inc. (AMGN) investors include: 1. Elevated debt levels (D/E ratio of 623.75) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amgen Inc.'s (AMGN) current debt and financial health profile: Total debt stands at $57.32B. The debt-to-equity ratio is 623.75, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.26, indicating adequate short-term liquidity. The quick ratio is 0.85. The company holds $12.04B in cash and equivalents. Free cash flow is positive at $7.44B, providing a cushion for debt servicing and shareholder returns.